Template:Androgen/anabolic steroid dosages for breast cancer

From HandWiki
v · d · e Androgen/anabolic steroid dosages for breast cancer
Route Medication Form Dosage Refs
Oral Methyltestosterone Tablet 30–200 mg/day [1][2][3][4]
Fluoxymesterone Tablet 10–40 mg 3x/day [1][5][6][7]
Calusterone Tablet 40–80 mg 4x/day [1][7]
Normethandrone Tablet 40 mg/day [2]
Buccal Methyltestosterone Tablet 25–100 mg/day [4]
Injection (IM or SC) Testosterone propionate Oil solution 50–100 mg 3x/week [1][2][8][6][7]
Testosterone enanthate Oil solution 200–400 mg 1x/2–4 weeks [9][10]
Testosterone cypionate Oil solution 200–400 mg 1x/2–4 weeks [10]
Mixed testosterone esters Oil solution 250 mg 1x/week [6]
Methandriol Aqueous suspension 100 mg 3x/week [8]
Androstanolone (DHT) Aqueous suspension 300 mg 3x/week [2][8][11]
Drostanolone propionate Oil solution 100 mg 1–3x/week [1][2][7]
Metenolone enanthate Oil solution 400 mg 3x/week [7]
Nandrolone decanoate Oil solution 50–100 mg 1x/1–3 weeks [12][13][14]
Nandrolone phenylpropionate Oil solution 50–100 mg/week [15][7]
Note: Dosages are not necessarily equivalent.
Template documentation

See also

References

  1. Jump up to: 1.0 1.1 1.2 1.3 1.4 Aurel Lupulescu (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6. https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57. 
  2. Jump up to: 2.0 2.1 2.2 2.3 2.4 Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170. 
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/083976s031lbl.pdf
  4. Jump up to: 4.0 4.1 Manuchair Ebadi (31 October 2007). Desk Reference of Clinical Pharmacology. CRC Press. pp. 434–. ISBN 978-1-4200-4744-8. https://books.google.com/books?id=ihxyHbnj3qYC&pg=PA434. 
  5. Michael Clinton Perry (2008). The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 369–. ISBN 978-0-7817-7328-7. https://books.google.com/books?id=CDADMzS0TKUC&pg=PA369. 
  6. Jump up to: 6.0 6.1 6.2 G. Martz (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 39–. ISBN 978-3-642-86282-3. https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA39. 
  7. Jump up to: 7.0 7.1 7.2 7.3 7.4 7.5 Janet Brotherton (1976). Sex Hormone Pharmacology. Academic Press. pp. 437. ISBN 978-0-12-137250-7. https://books.google.com/books?id=zt5sAAAAMAAJ. 
  8. Jump up to: 8.0 8.1 8.2 Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010. 
  9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009165s031lbl.pdf
  10. Jump up to: 10.0 10.1 American Medical Association. Division of Drugs; American Society for Clinical Pharmacology and Therapeutics (1983). "Androgens and Anabolic Steroids". AMA Drug Evaluations. American Medical Association. pp. 913–930. ISBN 978-0-89970-160-8. https://books.google.com/books?id=tsVKAQAAIAAJ. "TESTOSTERONE CYPIONATE [Andro-Cyp, Depo-Testosterone, T-Ionate-P.A.] TESTOSTERONE ENANTHATE [Andryl, Delatestryl] These long-acting, potent esters of testosterone can maintain the testosterone level within the normal range in males for two to four weeks. [...] For metastatic breast carcinoma in women, 200 to 400 mg every two or more weeks." 
  11. Segaloff, Albert; Horwitt, Benjamin N.; Cakabasi, Ralph A.; Murison, Path J.; Osser, Joskph V. Scht. (1955). "Hormonal therapy in cancer of the breast.VIII. The effect of dihydrotestosterone (Androstanolone) on clinical course and hormonal excretion". Cancer 8 (1): 82–86. doi:10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R. ISSN 0008-543X. 
  12. https://web.archive.org/web/20190309024812/https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf
  13. https://web.archive.org/web/20180128030754/http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf
  14. Ronald I. Shorr (11 April 2007). Drugs for the Geriatric Patient E-Book. Elsevier Health Sciences. pp. 844–. ISBN 978-1-4377-1035-9. https://books.google.com/books?id=-gmjBQAAQBAJ&pg=PA844. 
  15. W. Llewellyn McKone (11 November 2013). Osteopathic Athletic Health Care: Principles and practice. Springer. pp. 125–. ISBN 978-1-4899-3067-5. https://books.google.com/books?id=2bkACAAAQBAJ&pg=PA125.